Evaxion has announced the presentation of preclinical data regarding its vaccine candidate aimed at treating acute myeloid leukemia (AML). The data showcases the potential efficacy and safety profile of the vaccine in early-stage trials. This development marks a significant step in the company's efforts to address this challenging form of cancer through innovative immunotherapy approaches. Further details on the methodology and results of the preclinical studies were shared during the presentation.
Related Articles
Don't miss out on breaking stories and in-depth articles.